KKR Affiliate Provides $150M Financing to Support Apnimed’s AD109 Launch
KKR-owned HealthCare Royalty Partners committed a $150M senior secured facility to Apnimed, disbursing $50M upfront, $50M upon FDA approval of AD109, and $50M on a sales milestone. Apnimed will submit its New Drug Application for AD109 in Q2 2026 to fund its planned U.S. commercial launch.
1. Financing Terms
Apnimed entered a $150 million senior secured credit facility with HealthCare Royalty Partners, a KKR majority-owned affiliate. The structure provides $50 million at closing, $50 million upon FDA approval of AD109, and a final $50 million upon meeting a predefined sales milestone, alongside an interest-only period of four to five years and a low single-digit synthetic royalty on net sales.
2. AD109 Development and NDA Timeline
AD109 is a first-in-class oral therapy for obstructive sleep apnea combining aroxybutynin and atomoxetine. Apnimed plans to file its New Drug Application with the FDA in Q2 2026 following positive pivotal Phase 3 trial results, paving the way for a potential U.S. commercial launch.
3. Implications for KKR’s Healthcare Strategy
The financing underscores KKR’s continued commitment to biopharmaceutical innovation through HealthCare Royalty Partners. This investment aligns with its strategy of backing near-commercial assets, aiming to generate returns via credit yields and synthetic royalties as AD109 advances toward market approval.